Literature DB >> 9857104

Increased plasma levels of adrenomedullin in patients with pulmonary hypertension.

M Kakishita1, T Nishikimi, Y Okano, T Satoh, S Kyotani, N Nagaya, K Fukushima, N Nakanishi, S Takishita, A Miyata, K Kangawa, H Matsuo, T Kunieda.   

Abstract

Adrenomedullin, a potent hypotensive peptide, reduces blood pressure and pulmonary vascular resistance, and increases pulmonary blood flow. The mRNA for adrenomedullin and its receptor is highly expressed in the lung, suggesting a regulatory role for adrenomedullin in the pulmonary circulation. To investigate the clinical significance of adrenomedullin in patients with pulmonary hypertension, we studied the relationship between plasma levels of adrenomedullin and pulmonary haemodynamics. Venous, arterial and pulmonary arterial blood samples were obtained during cardiac catheterization and plasma levels of adrenomedullin were measured by specific radioimmunoassay in 33 consecutive patients with severe pulmonary hypertension (12 cases of primary pulmonary hypertension, 21 with chronic thromboembolic pulmonary hypertension; age 49+/-16 years, mean pulmonary arterial pressure 50+/-15mmHg). In addition, plasma levels of adrenomedullin were measured before and after acute nitric oxide inhalation. The changes in plasma adrenomedullin during the follow-up period of 10.3+/-4.3 months were also evaluated (n=5). Sixty-two healthy subjects served as the control group. Adrenomedullin was measured in an antecubital vein in the controls. Plasma levels of adrenomedullin were significantly higher in the patients with pulmonary hypertension than in the control subjects (10.1+/-8.7 versus 4.9+/-1.1pmol/l, P<0.01). Plasma levels of adrenomedullin, expressed as their natural logarithm, were significantly correlated with mean right atrial pressure (r=0.71, P<0.01), stroke volume (r=-0.63, P<0.01), total pulmonary resistance (r=0.60, P<0.01), mean pulmonary arterial pressure (r=0.37, P<0.05), and the natural logarithm of plasma atrial natriuretic peptide (r=0. 63, P<0.01). Plasma levels of adrenomedullin did not change significantly after nitric oxide inhalation, but significantly increased in association with the elevation of the total pulmonary resistance during the long-term follow-up period. These results suggest that plasma levels of adrenomedullin increase in proportion to the extent of pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9857104

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  14 in total

1.  Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification.

Authors:  Habib Bouzina; Göran Rådegran
Journal:  Pulm Circ       Date:  2020-06-15       Impact factor: 3.017

2.  CT-proET1 predicts pulmonary hemodynamics in Scleroderma-associated pulmonary hypertension.

Authors:  Henrik Ten Freyhaus; Daniel Dumitrescu; Sonja Schnorbach; Kai Kappert; Thomas Viethen; Martin Hellmich; Nicolas Hunzelmann; Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2015-02-24       Impact factor: 5.460

Review 3.  [Role of adrenomedullin in the pathogenesis and treatment of cardiovascular dysfunctions and sepsis].

Authors:  M Westphal; J Sander; H Van Aken; C Ertmer; H D Stubbe; M Booke
Journal:  Anaesthesist       Date:  2006-02       Impact factor: 1.041

Review 4.  Novel neurohumoral factors in congestive heart failure: adrenomedullin.

Authors:  J G Lainchbury
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

5.  The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.

Authors:  Masaru Obokata; Garvan C Kane; Yogesh N V Reddy; Vojtech Melenovsky; Thomas P Olson; Petr Jarolim; Barry A Borlaug
Journal:  Eur Heart J       Date:  2019-12-01       Impact factor: 29.983

6.  Haemodynamic and hormonal effects of adrenomedullin in patients with pulmonary hypertension.

Authors:  N Nagaya; T Nishikimi; M Uematsu; T Satoh; H Oya; S Kyotani; F Sakamaki; K Ueno; N Nakanishi; K Miyatake; K Kangawa
Journal:  Heart       Date:  2000-12       Impact factor: 5.994

7.  Treating pulmonary arterial hypertension: current treatments and future prospects.

Authors:  Shahzad G Raja; Shahbaz M Raja
Journal:  Ther Adv Chronic Dis       Date:  2011-11       Impact factor: 5.091

Review 8.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

9.  Two molecular forms of adrenomedullin in congenital heart disease.

Authors:  K Watanabe; T Nishikimi; M Takamuro; K Yasuda; Y Ishikawa; S Tanabe; O Yamada; N Nagaya; H Matsuoka; K Kangawa; S Echigo
Journal:  Pediatr Cardiol       Date:  2003-09-04       Impact factor: 1.655

Review 10.  Pulmonary vascular disease related to hemodynamic stress in the pulmonary circulation.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  Compr Physiol       Date:  2011-01       Impact factor: 9.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.